MedDRA preferred term · muscle pain

Myalgia: adverse event reports recording this term

167,188 reports to FDA record it, 2004–2026; 0.8% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

167,188
reports recording the term: 0.8% of all reports; 8,889
reports, 12 months to June 2026: 9,100 in the 12 months before; 57.8%
marked serious by the reporter: 57.4% across all reports; 1.9%
record death among outcomes, as reported: 9.1% across all reports

167,188 reports in FDA's adverse event database record the MedDRA term "Myalgia" (in plain words, muscle pain): 0.8% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

8,889 reports recorded it in the 12 months to June 2026, close to the 9,100 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 57.8% are marked serious, 1.9% include death among the outcomes and 18.6% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Lipitor, Repatha and Simvastatin. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Lipitor	HMG-CoA reductase inhibitor	5,883	10.7%
Repatha	PCSK9 inhibitor	5,216	3.4%
Simvastatin	HMG-CoA reductase inhibitor	4,997	14.1%
Crestor	HMG-CoA reductase inhibitor	4,548	10.3%
Atorvastatin	—	4,367	9.7%
Humira	—	4,035	0.6%
Dupixent	Interleukin-4 receptor alpha antagonist	3,729	0.8%
Prolia	RANK ligand inhibitor	3,451	2.5%
Enbrel	Tumor necrosis factor blocker	2,615	0.5%
Rosuvastatin	HMG-CoA reductase inhibitor	2,444	12.1%
Forteo	Parathyroid hormone analog	2,313	2.3%
Atorvastatin calcium	HMG-CoA reductase inhibitor	2,047	10.2%
Ciprofloxacin	Fluoroquinolone antibacterial	1,998	5%
Ezetimibe	Dietary cholesterol absorption inhibitor	1,880	16.4%
Uptravi	Prostacyclin receptor agonist	1,649	9.7%
Novothyrox	—	1,540	14.7%
Zocor	HMG-CoA reductase inhibitor	1,526	14.7%
Praluent	PCSK9 inhibitor	1,503	6.7%
Methotrexate	Folate analog metabolic inhibitor	1,435	0.7%
Xeljanz	Janus kinase inhibitor	1,403	0.9%
Lyrica	—	1,396	1.2%
Revlimid	Thalidomide analog	1,340	0.4%
Prednisone	Corticosteroid	1,316	0.7%
Xolair	Anti-IgE	1,214	1.9%
Pravastatin	—	1,198	16.9%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.8% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
HMG-CoA reductase inhibitor	24,414	11.9%	13.7%
Kinase inhibitor	9,365	1.1%	0.7%
PCSK9 inhibitor	6,872	3.8%	5.6%
Tumor necrosis factor blocker	6,558	0.6%	0.8%
Corticosteroid	4,775	0.6%	0.3%
Nonsteroidal anti-inflammatory drug	4,110	0.7%	0.1%
Bisphosphonate	3,955	4.1%	3.9%
Interleukin-4 receptor alpha antagonist	3,905	0.8%	1.1%
RANK ligand inhibitor	3,696	2.2%	0.8%
Fluoroquinolone antibacterial	3,479	3.9%	3.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20%82

2 to 110.4%607

12 to 170.8%1,399

18 to 4412.7%21,214

45 to 6427.5%45,910

65 to 7415.1%25,170

75 and over8.8%14,675

Age not given34.8%58,131

Patient sex

Female58.4%97,669

Male33%55,107

Not given8.6%14,412

Grey bar: all 20,646,523 reports in the database. 63.4% of these reports give the United States as the country.

Questions about "Myalgia"

What does "Myalgia" mean in an adverse event report?

In plain language: muscle pain. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record myalgia?

167,188 reports through June 2026 (0.8% of all reports), 8,889 of them in the latest 12 months.

Which drugs appear most often in these reports?

Lipitor (5,883), Repatha (5,216), Simvastatin (4,997), Crestor (4,548) and Atorvastatin (4,367). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.